Martin Williams

Pharma Services

• Built a partnered services business around a proprietary human Flare-in-a-Dish inflammasome assay, giving pharma partners translation-ready readouts that de-risk crystal disease programs.
• Head-to-head mechanism-of-action profiling of candidate compounds in human inflammasome models.
• Biomarker discovery and responder stratification from multi-omics analysis of patient samples.

Therapeutics & Diagnostics Discovery

• Directing internal discovery programs in gout and CPPD toward new therapeutics and diagnostics, built on the same human flare biology platform.

Company Building

• Authored the company's commercial thesis and strategy: fee-for-service pharma work funding an internal inflammasome-modulator discovery pipeline, with expansion from gout into CPPD.
• Stood the company up operationally: entity formation, EIN, facilities-use license with a regional research institute, incubator bench space, LIMS selection, independent IRB engagement.
• Built and run the business development process across hundreds of tracked pharma and biotech targets in gout, CPPD and inflammasome programs.

Direct-to-Consumer Solutions

• Mobile App — personally developed React Native app architecture
• Home-based In Vitro Diagnostic Medical Device — personally developed regulatory and production strategy for novel IVD device
• TikTok Education Channel — online education and spokesperson

Advanced Discovery Research

• Proteomics & Genomics analysis to identify novel drug targets and diagnostic tools (partnership with three universities)
• Prediction risk factor analysis to develop novel precision medicine analysis tool (partnered with Emory University faculty)

Clinical & Product Platform

• Participated in the development of the G-CAN 2024 international gout remission consensus criteria as a computed clinical engine that scores remission from patient-logged data.
• Designed the Flarebreak Gout Food Index, an original food-scoring algorithm and pipeline turning 436,708 rows of USDA nutrient data into 1,528 individually scored, citation-linked foods, released only after passing an 84-case calibration gate built from the published literature.
• Architected an AI gout coach to sit outside FDA medical device territory under the 2022 clinical decision support guidance — a corpus-only educational assistant trained on authoritative gout expert publications and findings.

Fractional Advisory / Independent Board Director Roles

• Board director for novel neuromodulation approach for intra-sleep delivery of closed-loop stimulation
• Regulatory advisory and FDA strategy for digital health company in neurological care management and behavioral intervention
• Commercialization and corporate strategy for novel physical assistive device academic spin-out
• Strategic advisor for novel pediatric epilepsy remote monitoring solution
• Fractional product marketing and commercialization for a venture-backed neurovascular device maker through a US stroke-catheter launch — Medicare coding and billing strategy, portfolio packaging, and product labeling.
• Venture building and first-in-human clinical strategy for a university synthetic biology spinout developing an engineered live biotherapeutic for Parkinson's disease — IND and IRB feasibility, and an investigator-initiated Phase 1 design with an academic movement disorder PI. Ran a physician KOL research program across 7 academic centers.

Private Equity Diligence and Operating Partnership

• Diligence and US-market entry strategy for private equity transaction of European healthcare entities in the neurological and rehabilitation space

• Founding team member and major participation in all company building aspects since day one including product development, strategic direction, operations, hiring, clinical strategy, KOL management and BOD management.
• Co-led initial device concept selection, design and generation of IP for world-first neurostimulation device targeting neurodegenerative disorders. Issued patents: 10,279,192, 10,293,177, 10,307,611, 10,702,705, 10,843,006, 11,141,604, 12,383,759, 12,434,072 including 30+ additional provisional patents.
• Developed advisory board of clinical, scientific and business KOLs and nurtured relationships with academic centers.
• Designed and executed Phase 1 human studies to prove safety and feasibility of device therapy concepts.
• Designed two Phase 2 multi-site clinical studies and participated in investigator selection, protocol design, site negotiations and enrollment ramp-up. (Etude Study, Overture Study). Studies resulted in significant clinically relevant outcomes including cognitive and functional benefits in Alzheimer's patients as well as a reduction in brain volume loss. Studies also showed improvement in white matter and myelin loss.
• Facilitated investigator-initiated study with PIs at Emory University and Georgia Tech to form a collaborative research program with the Emory Brain Health Center. (Flicker Study) Results published in 2021 showed significant engagement of cytokine and neuroimmunological proteins.
• Supported the preparation of registrational pivotal study including FDA discussions and clinical strategy.
• Supported the FDA interactions leading to Breakthrough Device Designation for the gamma sensory stimulation therapy, January 2021.
• Led the development of portfolio opportunities and the early-stage operations to pursue new indications in Acute Ischemic Stroke, Parkinson's disease, Lewy Body Dementia and Multiple Sclerosis.
• Established relationships with multiple pharmaceutical and medical device companies to explore strategic collaborations including out-licensing as well as co-development of new indication areas.

• Worked with global country leaders, leading ICAD KOLs and internal colleagues to spearhead the development of a 5 year plan to grow ICAD product franchise from $25M to $65M with support from Executive Team and global business leaders.
• Won funding from Executive Team for fundamentally new ICAD therapy concept with >$15M budget.
• Managed the cross-functional effort to design new ICAD devices and the subsequent clinical trial strategy in the US and Greater China.
• Managed relationships with six global PIs for five unique clinical trials in the US, Taiwan, China, and Hong Kong.
• Identified new BD opportunities and brought new partnerships/acquisitions to internal investment committee.
• Developed and nurtured productive relationships with the top 25 KOLs in the world on the subject of intracranial atherosclerosis, including the leading US, Chinese, Taiwanese, Hong Kong and European subject matter experts.

• Led the marketing due diligence on the $262M acquisition of NASDAQ:ROCM through an international VOC and secondary research effort; led international integration summit with European marketing directors post-acquisition.
• Chosen to research and present to Chris Holland, corporate CFO, on question from Board of Directors: Should BCR vertically integrate into DME space? Resulted in shift in understanding for BOD, culminating in acquisition of NASDAQ:LBMH for $181M (Nov 2015).
• Managed the entire diligence process for acquiring a novel urological diagnostic device being developed by start-up; recommended not to buy company (May 2014) – advised startup company through new funding round (Oct 2014).
• Managed the ongoing process to create semi-annual presentation for CEO, COO and CFO on new global product pipeline working with over 40 engineering and marketing VPs and directors across 4 franchises and $850M business.
• Working with VP, Marketing, created C-Suite level three year strategic plan for $535M US division.
• Designed multiple international market VOC assessments for the entire $850M global division to identify unmet needs and market trends in China, Japan, Brazil, Mexico, and Colombia.

• Created turnaround strategy and pitch deck for a turnaround acquisition for Portaero, a homogeneous emphysema therapy suffering from poor clinical trial results. Delivered pitch to Versant, Aberdare, and NEA Ventures.
• Analyzed clinical trial results and device performance for Sebacia, a novel, laser-based dermatology therapy.
• Developed a commercialization strategy model for introducing a venture-backed start-up medical device in Germany.

• Spearheaded the mechanical design, testing, and validation for robotic production equipment for a high-volume, disposable brain monitoring sensor producing more than 7 million units per year.
• Designed and built a semi-automated production factory for a disposable brain-monitoring sensor resulting in a system capable of producing 350,000 units per year.
• Led all complaint resolution and cross-functional Six Sigma production engineering tasks for Shingo prize-winning factory producing 7M sensors annually with sales of $85M.

• Managed cross-functional team of five engineers and scientists to design custom bioagent-sample preparation robot.